The angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor axis: A potential target for treating thrombotic diseases

Thrombosis and Haemostasis

Volumn 108, Issue 6, 2012, Pages 1089-1096

  Fraga Silva, Rodrigo A ^a   Da Silva, Danielle G ^a   Montecucco, Fabrizio ^b,c   Mach, François ^b   Stergiopulos, Nikolaos ^a   da Silva, Rafaela F ^a,d   dos Santos, Robson A Souza ^a  

^a EPFL   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY OF GENOA   (Italy)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Angiotensin converting enzyme 2; Angiotensin (1 7); Platelet; Receptor mas; Thrombosis

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN [1-7] [7 DEXTRO ALANINE]; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN[1-7]; CYCLIC AMP; CYCLIC GMP; CYCLODEXTRIN; MAS RECEPTOR; NITRIC OXIDE; PERINDOPRIL; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTACYCLIN; PROSTACYCLIN RECEPTOR; PROTEIN KINASE B; QUINAPRIL; RECEPTOR PROTEIN; TELMISARTAN; UNCLASSIFIED DRUG;

HEMOSTASIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; THROMBOSIS;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HEMOSTASIS; HUMANS; MODELS, CARDIOVASCULAR; PEPTIDYL-DIPEPTIDASE A; PROTO-ONCOGENE PROTEINS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, G-PROTEIN-COUPLED; RENIN-ANGIOTENSIN SYSTEM; THROMBOSIS;

EID: 84870884733     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-06-0396     Document Type: Review

References (93)

1. Willoughby S, Holmes A, Loscalzo J. Platelets and cardiovascular disease. Eur J Cardiovasc Nurs 2002; 1: 273-288.
2. Vazzana N, Ranalli P, Cuccurullo C, et al. Diabetes mellitus and thrombosis. Thromb Res 2012; 129: 371-377.
3. Lip GY. Hypertension, platelets, and the endothelium: the "thrombotic paradox"of hypertension (or "Birmingham paradox") revisited. Hypertension 2003; 41: 199-200.
4. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3: e442.
5. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res 2001; 88: 756-762.
6. Bombeli T, Mueller M, Haeberli A. Anticoagulant properties of the vascular en-dothelium. Thromb Haemost 1997; 77: 408-423.
7. Crawley JT, Zanardelli S, Chion CK, et al. The central role of thrombin in hemos-tasis. J Thromb Haemost 2007; 5 (Suppl 1): 95-101.
8. Griendling KK, Murphy TJ, Alexander RW. Molecular biology of the renin-angio-tensin system. Circulation 1993; 87: 1816-1828.
9. Kucharewicz I, Pawlak R, Matys T, et al. Angiotensin-(1-7): an active member of the renin-angiotensin system. J Physiol Pharmacol 2002; 53: 533-540.
10. Dzau VJ. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001; 37: 1047-1052.
11. Remkova A, Remko M. The role of renin-angiotensin system in prothrombotic state in essential hypertension. Physiol Res 2010; 59: 13-23.
12. de Gasparo M, Catt KJ, Inagami T, et al. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415-472.
13. Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 2002; 277: 14838-14843.
14. Tipnis SR, Hooper NM, Hyde R, et al. A human homolog of angiotensin-convert-ing enzyme. Cloning and functional expression as a captopril-insensitive car-boxypeptidase. J Biol Chem 2000; 275: 33238-33243.
15. Donoghue M, Hsieh F, Baronas E, et al., A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87: E1-E9.
16. Santos RA, Simoes e Silva AC, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003; 100: 8258-8263.
17. Ferreira AJ, Santos RA, Bradford CN, et al. Therapeutic implications of the vaso-protective axis of the renin-angiotensin system in cardiovascular diseases. Hypertension 2010; 55: 207-213.
18. Zisman LS, Meixell GE, Bristow MR, et al. Angiotensin-(1-7) formation in the intact human heart: in vivo dependence on angiotensin II as substrate. Circulation 2003; 108: 1679-1681.
19. Sampaio WO, Henrique de Ca s tro C, Santos RA, et al. Angi o tensin-(1 -7) cou n ter-regulates angiotensin II signaling in human endothelial cells. Hypertension 2007; 50: 1093-1098.
20. Ferrario CM, Chappell MC, Tallant EA, et al., Counterregulatory actions of angio-tensin-(1-7). Hypertension 1997; 30: 535-541.
21. Ferreira AJ Santos RA. Cardiovascular actions of angiotensin-(1-7). Braz J Med Biol Res 2005; 38: 499-507.
22. Fraga-Silva RA, Pinheiro S V, Gonçalves AC, et al. The antithrombotic effect of an-giotensin-(1-7) involves mas-mediated NO release from platelets. Mol Med 2008; 14: 28-35.
23. Fraga-Silva RA, Sorg BS, Wankhede M, et al. ACE2 activation promotes anti-thrombotic activity. Mol Med 2010; 16: 210-215.
24. Kucharewicz I, Pawlak R, Matys T, et al. Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7). Hypertension 2002; 40: 774-779.
25. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002; 89: 3A-10A.
26. Bader M. Tissue renin-angiotensin-aldosterone systems: Targets for pharmacological therapy. Annu Rev Pharmacol Toxicol 2010; 50: 439-465.
27. Montecucco F, Pende A, Mach F. The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies. Mediators Inflamm. 2009; 2009: 752406.
28. Kokubu T, Ueda E, Joh T, et al. Purification and properties of angiotensin I-con-verting enzyme in human lung and its role on the metabolism of vasoactive pep-tides in pulmonary circulation. Adv Exp Med Biol 1979; 120B: 467-475.
29. Inagami T. A memorial to Robert Tiegerstedt: the centennial of renin discovery. Hypertension 1998; 32: 953-957.
30. Touyz RM, Berry C. Recent advances in angiotensin II signaling. Braz J Med Biol Res 2002; 35: 1001-1015.
31. Allen AM, Zhuo J, Mendelsohn FA. Localization and function of angiotensin AT1 receptors. Am J Hypertens 2000; 13: 31S-38S.
32. Matsusaka T, Ichikawa I. Biological functions of angiotensin and its receptors. Annu Rev Physiol 1997; 59: 395-412.
33. Touyz RM. Reactive oxygen species and angiotensin II signaling in vascular cells --implications in cardiovascular disease. Braz J Med Biol Res 2004; 37: 1263-1273.
34. Brown NJ, Vaughan DE. Prothrombotic effects of angiotensin. Adv Intern Med 2000; 45: 419-429.
35. Widdop RE, Matrougui K, Levy BI, et al. AT2 receptor-mediated relaxation is preserved after long-term AT1 receptor blockade. Hypertension 2002; 40: 516-520.
36. Savoia C, D'Agostino M, Lauri F, et al. Angiotensin ty pe 2 receptor in hy per tensive cardiovascular disease. Curr Opin Nephrol Hypertens 2011; 20: 125-132.
37. Schiffrin EL. Vascular and cardiac benefits of angiotensin receptor blockers. Am J Med 2002; 113: 409-418.
38. Ma TK, Kam KK, Yan BP, et al. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol 2010; 160: 1273-1292.
39. Nicholls MG, Richards AM, Agarwal M. The importance of the renin-angiotensin system in cardiovascular disease. J Hum Hypertens 1998; 12: 295-299.
40. Santos RA, Ferreira AJ, Pinheiro S V, et al. Angiotensin-(1-7) and its receptor as a potential targets for new cardiovascular drugs. Expert Opin Investig Drugs 2005; 14: 1019-1031.
41. Xu P, Costa-Goncalves AC, Todiras M, et al. Endothelial dysfunction and elevated blood pressure in MAS gene-deleted mice. Hypertension 2008; 51: 574-580.
42. Rabelo LA, Alenina N, Bader M. ACE2-angiotensin-(1-7)-Mas axis and oxidative stress in cardiovascular disease. Hypertens Res 2011; 34: 154-160.
43. Iwai M, Horiuchi M. Devil and angel in the renin-angiotensin system: ACE-an-giotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis. Hypertens Res 2009; 32: 533-536.
44. Santos RA, Campagnole-Santos MJ, Andrade S P. Angiotensin-(1-7): an update. Regul Pept 2000; 91: 45-62.
45. Dielis AW, Smid M, Spronk HM, et al. The prothrombotic paradox of hypertension: role of the renin-angiotensin and kallikrein-kinin systems. Hypertension 2005; 46: 1236-1242.
46. Dielis AW, Smid M, Spronk HM, et al. Changes in fibrinolytic activity after angio-tensin II receptor blockade in therapy-resistant hypertensive patients. Journal of thrombosis and haemostasis: J Thromb Haemost 2007; 5: 1509-1515.
47. Matsumoto T, Minai K, Horie H, et al. Angiotensin-converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients. J Am Coll Cardiol 2003; 41: 1373-1379.
48. Brown NJ, Agirbasli MA, Williams GH, et al. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 1998; 32: 965-971.
49. Minai K, Matsumoto T, Horie H, et al. Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: effects of angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2001; 37: 1565-1570.
50. Goodfield NE, Newby DE, Ludlam CA, et al., Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation 1999; 99: 2983-2985.
51. Erdem Y, Usalan C, Haznedaroglu IC, et al. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am J Hypertens 1999; 12: 1071-1076.
52. Sakata K, Pawlak R, Urano T, et al. Effects of a long-term pharmacological interruption of the renin-angiotensin system on the fibrinolytic system in essential hypertension. Pathophysiol Haemost Thromb 2002; 32: 67-75.
53. Koh KK, Chung WJ, Ahn J Y, et al., Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo-controlled study. Atherosclerosis 2004; 177: 155-160.
54. Makris TK, Stavroulakis GA, Krespi PG, et al. Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol. Am J Hy-pertens 2000; 13: 783-788.
55. Seljeflot I, Moan A, Kjeldsen S, et al. Effect of angiotensin II receptor blockade on fibrinolysis during acute hyperinsulinemia in patients with essential hypertension. Hypertension 1996; 27: 1299-1304.
56. Remkova A, Kratochvil'ova H, Durina J. Impact of the therapy by renin-ang ioten-sin system targeting antihypertensive agents perindopril versus telmisartan on prothrombotic state in essential hypertension. J Hum Hypertens 2008; 22: 338-345.
57. Hlubocká Z, Umnerová V, Heller S, et al. Circulating intercellular cell adhesion molecule-1, endothelin-1 and von Willebrand factor-markers of endothelial dysfunction in uncomplicated essential hypertension: the effect of treatment with ACE inhibitors. J Hum Hypertens 2002; 16: 557-562.
58. Hornig B, Arakawa N, Haussmann D, et al. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. Circulation 1998; 98: 2842-2848.
59. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996; 94: 258-265.
60. Taddei S, Virdis A, Ghiadoni L, et al. Effects of antihypertensive drugs on endothe-lial dysfunction: clinical implications. Drugs 2002; 62: 265-284.
61. Ceconi C, Fox KM, Remme WJ, et al. ACE inhibition with perindopril and en-dothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 2007; 73: 237-246.
62. Scientific Committee of the PERTINENT Sub-Study, EUROPA-PERTINENT Investigators. PERTINENT--perindopril-thrombosis, inflammation, endothelial dysfunction and neurohormonal activation trial: a sub-study of the EUROPA study. Cardiovasc Drugs Ther 2003; 17: 83-91.
63. Riondino S, Pignatelli P, Pulcinelli FM, et al. Platelet hyperactivity in hypertensive older patients is controlled by lowering blood pressure. J Am Geriatr Soc 1999; 47: 943-947.
64. Okrucka A, Pechan J, Kratochvilova H. Effects of the angiotensin-converting enzyme (ACE) inhibitor perindopril on endothelial and platelet functions in essential hypertension. Platelets 1998; 9: 63-67.
65. Levy PJ, Yunis C, Owen J, et al. Inhibition of platelet aggregability by losartan in essential hypertension. Am J Cardiol 2000; 86: 1188-1192.
66. Kalinowski L, Matys T, Chabielska E, et al., Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension 2002; 40: 521-527.
67. Sato Y, Fujii S, Imagawa S, et al. Platelet aggregability in patients with hypertension treated with angiotensin II type 1 receptor blockers. J Atheroscler Thromb 2007; 14: 31-35.
68. Iyer SN, Chappell MC, Averill DB, et al. Vasodepressor actions of angioten-sin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension 1998; 31: 699-705.
69. Iyer SN, Ferrario CM, Chappell MC. Angiotensin-(1-7) contributes to the antihy-pertensive effects of blockade of the renin-angiotensin system. Hypertension 1998; 31: 356-361.
70. Kucharewicz I, Chabielska E, Pawlak D, et al. The antithrombotic effect of angio-tensin-(1-7) closely resembles that of losartan. J Renin Angiotensin Aldosterone Syst 2000; 1: 268-272.
71. Silva DM, Gomes-Filho A, Olivon VC, et al. Swimming training improves the vasodilator effect of angiotensin-(1-7) in the aorta of spontaneously hypertensive rat. J Appl Physiol 2011; 111: 1272-1277.
72. Sampaio WO, Souza dos Santos RA, Faria-Silva R, et al. Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 2007; 49: 185-192.
73. Rajendran S, Chirkov YY, Campbell DJ, et al. Angiotensin-(1-7) enhances anti-aggregatory effects of the nitric oxide donor sodium nitroprusside. J Cardiovasc Pharmacol 2005; 46: 459-463.
74. Fraga-Silva RA, Costa-Fraga F P, De Sousa FB, et al. An orally active formulation of angiotensin-(1-7) produces an antithrombotic effect. Clinics (Sao Paulo) 2011; 66: 837-841.
75. Senchenkova EY, Russell J, Almeida-Paula LD et al. Angiotensin II-mediated microvascular thrombosis. Hypertension 2010; 56: 1089-1095.
76. Senchenkova EY, Russell J, Kurmaeva E, et al. Role of T lymphocytes in angioten-sin II-mediated microvascular thrombosis. Hypertension 2011; 58: 959-965.
77. Zhang JD, Patel MB, Song YS, et al. A novel role for type 1 Angiotensin receptors on T lymphocytes to limit target organ damage in hypertension. Circ Res 2012; 110: 1604-1617.
78. Ferreira AJ, Bader M, Santos RA. Therapeutic targeting of the angiotensin-con-verting enzyme 2/Angiotensin-(1-7)/Mas cascade in the renin-angiotensin system: a patent review. Expert Opin Ther Pat 2012; 22: 567-574.
79. Ferreira AJ, Murça TM, Fraga-Silva RA, et al. New cardiovascular and pulmonary therapeutic strategies based on the Angiotensin-converting enzyme 2/angioten-sin-(1-7)/mas receptor axis. Int J Hypertens 2012; 2012: 147825.
80. Yamada K, Iyer SN, Chappell MC, et al. Converting enzyme determines plasma clearance of angiotensin-(1-7). Hypertension 1998; 32: 496-502.
81. Lula I, Denadai AL, Resende JM, et al. Study of angiotensin-(1-7) vasoactive pep-tide and its beta-cyclodextrin inclusion complexes: complete sequence-specific NMR assignments and structural studies. Peptides 2007; 28: 2199-2210.
82. Uekama K. Design and evaluation of cyclodextrin-based drug formulation. Chem Pharm Bull (Tokyo) 2004; 52: 900-915.
83. Salústio PJ, Pontes P, Conduto C, et al. Advanced technologies for oral controlled release: cyclodextrins for oral controlled release. AAPS PharmSciTech 2011; 12: 1276-92.
84. Rajewski RA, Stella VJ. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J Pharm Sci 1996; 85: 1142-1169.
85. Roux M, Perly B, Djedaini-Pilard F. Self-assemblies of amphiphilic cyclodextrins. Eur Biophys J 2007; 36: 861-867.
86. Silva-Barcellos NM, Frézard F, Caligiorne S, et al. Long-lasting cardiovascular effects of liposome-entrapped angiotensin-(1-7) at the rostral ventrolateral medulla. Hypertension 2001; 38: 1266-1271.
87. Silva-Barcellos NM, Caligiorne S, dos Santos RA, et al. Site-specific microinjec-tion of liposomes into the brain for local infusion of a short-lived peptide. J Control Release 2004; 95: 301-307.
88. Kluskens LD, Nelemans SA, Rink R, et al. Angiotensin-(1-7) with thioether bridge: an angiotensin-converting enzyme-resistant, potent angiotensin-(1-7) analog. J Pharmacol Exp Ther 2009; 328: 849-854.
89. Wiemer G, Dobrucki LW, Louka FR, et al. AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium. Hypertension 2002; 40: 847-852.
90. Savergnini SQ, Beiman M, Lautner RQ, et al. Vascular relaxation, antihyper tensive effect, and cardioprotection of a novel peptide agonist of the MAS receptor. Hypertension 2010; 56: 112-120.
91. Pinheiro SV, Simões e Silva AC, Sampaio WO, et al. Nonpeptide AV E 0991 is an an-giotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension 2004; 44: 490-496.
92. Lemos VS, Silva DM, Walther T, et al. The endothelium-dependent vasodilator effect of the nonpeptide Ang(1-7) mimic AV E 0991 is abolished in the aorta of mas-knockout mice. J Cardiovasc Pharmacol 2005; 46: 274-279.
93. Hernández Prada JA, Ferreira AJ, Katovich MJ, et al. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension 2008; 51: 1312-1317.